SCHEMBL5714516

SCHEMBL5714516

O=C(Oc1ccc(CCOc2cccnc2)cc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.54
HPGD P15428 1/20 0.54
TRPV1 Q8NER1 2/20 0.51
CYP3A4 P08684 1/20 0.50
TRPA1 O75762 1/20 0.50
KDM4E B2RXH2 3/20 0.49
HTT P42858 4/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
IDE P14735 1/20 0.47
LIPE Q05469 4/20 0.46
LMNA P02545 4/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.46
BCHE P06276 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714123 0.90 SMN1; SMN2 (0.57) SMN1; SMN2HPGDTRPV1TRPA1KDM4E
SCHEMBL5714971 0.88 ME2 (0.48) SMN1; SMN2TRPV1CYP3A4TRPA1KDM4E
SCHEMBL5715387 0.86 ME2 (0.46) SMN1; SMN2HPGDCYP3A4TRPA1KDM4E
SCHEMBL5714420 0.86 TRPA1 (0.49) TRPV1CYP3A4TRPA1
SCHEMBL5714268 0.86 HTT (0.55) SMN1; SMN2HPGDTRPV1TRPA1KDM4E
SCHEMBL5715298 0.86 SLC6A7 (0.48) SMN1; SMN2CYP3A4TRPA1KDM4EMAPK1
SCHEMBL5714805 0.86 SLC6A7 (0.44) SMN1; SMN2CYP3A4TRPA1KDM4EMAPK1
SCHEMBL5715091 0.85 HSD17B10 (0.54) SMN1; SMN2HPGDCYP3A4TRPA1KDM4E
SCHEMBL5714344 0.82 SMN1; SMN2 (0.54) SMN1; SMN2HPGDTRPV1TRPA1KDM4E
SCHEMBL5714721 0.82 SMN1; SMN2 (0.65) SMN1; SMN2HPGDTRPV1TRPA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC SMN1; SMN2 2732/4885HPGD 793/4885TRPV1 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.